Salsalate Pill

Phase 1Small molecule

PPenn State University

Salsalate Pill is one of 38 small molecule programs targeting Endometriosis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EndometriosisActive, not recruiting

EndometriosisPhase 1

Active, not recruiting

Competition

Competitive Landscape

199 competitors in Endometriosis

#DrugCompanyPhaseTrials

Orilissa

AbbVie

Phase 3

16 2

Revia

Teva

Phase 3

1 3

Lupron

EEastern Cooperative Oncology Group

Phase 3

1 4

Firmagon

Ferring

Phase 3

1 5

Trental

VValidus Pharmaceuticals

Phase 3

1 6

Esketamine Hydrochloride

TThe Second Hospital of Anhui Medical University

Phase 3

1 7

Add-Back

KKissei Pharmaceutical Co., Ltd.

Phase 3

4 8

Visanne

Bayer

Phase 3

2 9

Triptorelin Acetate PR 1-Month

Ipsen

Phase 3

1 10

NPC-01

NNobelpharma

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Endometriosis

NCT05069740

Clinical

Trials by Indication[1]

Endometriosis1 trial

Endometriosis and Microvascular Dysfunction: Role of Inflammation

Recruiting·PPenn State University·Phase 1·NCT05069740·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Salsalate Pill. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Salsalate Pill compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Salsalate Pill. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Penn State University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: PPenn State University

Salsalate Pill

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Endometriosis1 trial

References

Drug Info

Quick Facts

Related News